A novel phycoerythrin-derived peptide from Colaconema formosanum: Synthesis, in vitro, and in silico study on angiotensin-converting enzyme (ACE) inhibitory activity

IF 3.4 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biocatalysis and agricultural biotechnology Pub Date : 2024-12-01 DOI:10.1016/j.bcab.2024.103452

Seto Windarto , Meng-Chou Lee , Happy Nursyam , Jue-Liang Hsu

{"title":"A novel phycoerythrin-derived peptide from Colaconema formosanum: Synthesis, in vitro, and in silico study on angiotensin-converting enzyme (ACE) inhibitory activity","authors":"Seto Windarto , Meng-Chou Lee , Happy Nursyam , Jue-Liang Hsu","doi":"10.1016/j.bcab.2024.103452","DOIUrl":null,"url":null,"abstract":"<div><div><em>Colaconema formosanum</em>, the red algae used in this study, has never been documented for its bioactivities as an angiotensin-converting enzyme inhibitor (ACEI). This study aims to discover ACEI derived from <em>C. formosanum</em> with a mixture of enzymes and orthogonal bioassay-guided fractionation through <em>in vitro</em> and <em>in silico</em> approaches. LRDGEIILR (LR-9) was isolated from the protein hydrolysate of <em>C. formosanum</em> digested by a combination of proteases (pepsin and thermolysin). It is derived from phycoerythrin, a protein abundant in most red algae. The LR-9 has an IC<sub>50</sub> value of 94.28 ± 1.84 μM. The kinetics of inhibition revealed LR-9 to be a competitive inhibitor. The results of kinetic studies were rationalized further using molecular docking, which showed that LR-9 interacts preferentially with critical residues in the ACE active site. Based on the toxicity prediction, LR-9 was non-toxic. This study suggests that ACEI peptides extracted from <em>C. formosanum</em> could be an alternative source for developing hypertension-treating functional foods.</div></div>","PeriodicalId":8774,"journal":{"name":"Biocatalysis and agricultural biotechnology","volume":"62 ","pages":"Article 103452"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biocatalysis and agricultural biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878818124004365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Colaconema formosanum, the red algae used in this study, has never been documented for its bioactivities as an angiotensin-converting enzyme inhibitor (ACEI). This study aims to discover ACEI derived from C. formosanum with a mixture of enzymes and orthogonal bioassay-guided fractionation through in vitro and in silico approaches. LRDGEIILR (LR-9) was isolated from the protein hydrolysate of C. formosanum digested by a combination of proteases (pepsin and thermolysin). It is derived from phycoerythrin, a protein abundant in most red algae. The LR-9 has an IC₅₀ value of 94.28 ± 1.84 μM. The kinetics of inhibition revealed LR-9 to be a competitive inhibitor. The results of kinetic studies were rationalized further using molecular docking, which showed that LR-9 interacts preferentially with critical residues in the ACE active site. Based on the toxicity prediction, LR-9 was non-toxic. This study suggests that ACEI peptides extracted from C. formosanum could be an alternative source for developing hypertension-treating functional foods.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biocatalysis and agricultural biotechnology Agricultural and Biological Sciences-Agronomy and Crop Science

CiteScore

7.70

自引率

2.50%

发文量

308

审稿时长

48 days

期刊介绍： Biocatalysis and Agricultural Biotechnology is the official journal of the International Society of Biocatalysis and Agricultural Biotechnology (ISBAB). The journal publishes high quality articles especially in the science and technology of biocatalysis, bioprocesses, agricultural biotechnology, biomedical biotechnology, and, if appropriate, from other related areas of biotechnology. The journal will publish peer-reviewed basic and applied research papers, authoritative reviews, and feature articles. The scope of the journal encompasses the research, industrial, and commercial aspects of biotechnology, including the areas of: biocatalysis; bioprocesses; food and agriculture; genetic engineering; molecular biology; healthcare and pharmaceuticals; biofuels; genomics; nanotechnology; environment and biodiversity; and bioremediation.